Scoring design

Approaches to Stop Hypertension (DASH), study in the US the Mediterranean Diet Score, designed to estimate adherence to the Greek variant of the Mediterranean diet and the Itahan Mediterranean Index specifically developed to better estimate the adherence to the Italian Mediterranean diet. ° Although all these dietary patterns tended to be inversely associated with at least one type of stroke, the Itahan Mediterranean Index performed somewhat better than the others, having significant inverse associations with all t3 es of stroke and ischemic stroke and also a tendency to be inversely associated with hemorrhagic stroke. 

Bdhm H-J 1994 The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure J. Comp.-Aided Mol. Design 8 243-56... 

I-J 1994. The Development of a Simple Empirical Scoring Fimction to Estimate the Binding istant for a Protein-ligand Complex of Known Three-Dimensional Structure. Journal of nputer-Aided Molecular Design 8 243-256. 

Eldridge M D, C W Murray, T R Auton, G V Paoliniand R P Mee 1997. Empirical Scoring Functions 1 The Development of a Fast Empirical Scoring Fimction to Estimate the Binding Affinity of Ligand in Receptor Complexes. Journal of Computer-Aided Molecular Design 11 425-445. 

In summary, we found that the students received lower scores on items that were at different pressures than on items with the same amount of pressure. Also, we found that although the students learned the concept of diffusion in their seventh grade biology class, they did not generate the conception of diffusion in a submicro-scopic maimer. Instead, they tended to conceptualize the diffusion of the particles in a more intuitive way (the heavier object sinking to the bottom of the container) than in a scientific model that was designed to delineate the random nature of the particle motion. 

Liang SD, Grishin NV. Effective scoring function for protein sequence design. Proteins 2004 54 271-81. 

ECASS-II was designed to test a lower dose of rt-PA (0.9 mg/kg) during the same 0-6-hours time period after stroke onset, using similar inclusion criteria as in ECASS-I. ° The primary endpoint was the proportion with a favorable outcome on the mRS scale (defined as a score of 0 or 1). There was no difference in this outcome between rt-PA-treated and placebo controls (40% vs. 37%, p = 0.28). A separate analysis of the 158 subjects enrolled within 3 hours of stroke onset also showed no difference in the proportion with a favorable outcome (42% vs. 38%, p = 0.63) this result, however, must be treated with caution because in ECASS-II there was a substantially lower number of patients treated within 3 hours of stroke onset, compared to the 1995 NINDS rt-PA study. Parenchymal hematoma on post-treatment CT was seen in 12% of rt-PA-treated and 3% of placebo patients (p < 0.001). The 90-day mortality rate was 11 % for the rt-PA group and 11 % for the placebo group (p = 0.54). Protocol violations were much less frequent in ECASS-II compared to ECASS-I (9% vs. 18%), probably because of standardized training in CT interpretation at the study sites. 

---